Tenax pauses LEVEL-2 enrollment to amend criteria; seeks Type C FDA meeting on levosimendan

TENAX THERAPEUTICS, INC.

Tenax has temporarily paused enrollment in its LEVEL-2 trial of TNX-103 (levosimendan) in PH-HFpEF in order to amend the trial's enrollment criteria.
The amended criteria follow key learnings from the recently completed Phase 3 LEVEL trial; enrollment may resume at each site as the amended protocol goes into effect there.
Company requested a Type C meeting with the U.S. Food and Drug Administration to discuss the overall development of levosimendan.
Enriched enrollment targets patients LEVEL results suggest are most likely to show improved exercise tolerance on LEVEL-2's primary endpoint.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.